TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07473128: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Sponsor: Pharmacosmos A/S · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07473128 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07473128 Rescue Dossier →